Metabolic & body composition
Triple Regulator (GLP-1/GIP/glucagon)
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending.
Also known as LY3437943
An investigational triple agonist (GLP-1, GIP and glucagon) in late-stage clinical trials — not approved, not prescribable.
What it is
The triple regulator adds glucagon-receptor agonism to the GLP-1/GIP dual mechanism. The glucagon arm is what makes it different: alongside appetite and insulin effects, it appears to raise energy expenditure directly. Phase 2 results reported mean weight reduction around 24% at 48 weeks at the highest dose — the largest figure published for a pharmacologic agent — and phase 3 trials are ongoing.
What it's studied for
- Phase 2 weight reduction of roughly 24% at 48 weeks at the top dose
- Liver-fat reduction in MASLD populations
- Glycemic control in type 2 diabetes
- Ongoing phase 3 TRIUMPH program
How it's used in practice
- There is no approved product, no approved dosing and no legitimate prescription channel
- Material sold online is unregulated, unverified for identity and purity, and labeled research use only
- The honest answer for anyone asking today is to wait for approval or ask about enrolling in a trial
What you should know before asking about it
- Not FDA-approved for any use; not for human or animal consumption
- The glucagon arm can raise heart rate and affect glucose in ways still being characterized in trials
- Long-term safety is unknown by definition — phase 3 is where that gets answered
- We do not present this as a treatment we provide as medical care
Frequently asked questions.
- What is Triple Regulator (GLP-1/GIP/glucagon)?
- The triple regulator adds glucagon-receptor agonism to the GLP-1/GIP dual mechanism. The glucagon arm is what makes it different: alongside appetite and insulin effects, it appears to raise energy expenditure directly. Phase 2 results reported mean weight reduction around 24% at 48 weeks at the highest dose — the largest figure published for a pharmacologic agent — and phase 3 trials are ongoing.
- What is Triple Regulator (GLP-1/GIP/glucagon) studied for?
- Published and ongoing research looks at phase 2 weight reduction of roughly 24% at 48 weeks at the top dose; liver-fat reduction in MASLD populations; glycemic control in type 2 diabetes; ongoing phase 3 TRIUMPH program. These are areas of study, not promised outcomes.
- Is Triple Regulator (GLP-1/GIP/glucagon) FDA-approved?
- Triple Regulator (GLP-1/GIP/glucagon) has not been evaluated by the FDA. Elevate Chicago lists it for education and research reference only — it is not prescribed as medical care and is not intended for human consumption.
- How is Triple Regulator (GLP-1/GIP/glucagon) typically used?
- There is no approved product, no approved dosing and no legitimate prescription channel Material sold online is unregulated, unverified for identity and purity, and labeled research use only The honest answer for anyone asking today is to wait for approval or ask about enrolling in a trial Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.
- What are the risks and unknowns with Triple Regulator (GLP-1/GIP/glucagon)?
- Not FDA-approved for any use; not for human or animal consumption The glucagon arm can raise heart rate and affect glucose in ways still being characterized in trials Long-term safety is unknown by definition — phase 3 is where that gets answered We do not present this as a treatment we provide as medical care
Sources
- 1.Published literature on Triple Regulator (GLP-1/GIP/glucagon) LY3437943— PubMed, U.S. National Library of Medicine
- 2.Compounding and the FDA: questions and answers— U.S. Food & Drug Administration
- 3.Bulk drug substances nominated for use in compounding under section 503A— U.S. Food & Drug Administration
- 4.Test directory and patient service center locator— Quest Diagnostics
About this page
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending. Educational content only — not medical advice, not a diagnosis, and not an offer to sell any prescription product.
This page is educational reference material. It is not medical advice, not a diagnosis, and not an offer to sell any product. Prescription therapies are dispensed only through licensed, FDA-registered compounding pharmacies after a physician evaluation. Compounds identified as research use only are not FDA-approved, are not prescribed as medical care, and are not intended for human or animal consumption. Availability, formulations and regulatory status change over time.
More in Metabolic & body composition
Single Regulator (GLP-1) — semaglutide
Semaglutide, listed as Single Regulator (GLP-1) because compounded formulations cannot be marketed under the drug's commercial name. A GLP-1 medication containing an active ingredient also found in FDA-approved products; compounded formulations are not themselves FDA-approved.
Dual Regulator (GLP-1/GIP) — tirzepatide
Tirzepatide, listed as Dual Regulator (GLP-1/GIP) because compounded formulations cannot be marketed under the drug's commercial name. A GIP/GLP-1 medication containing an active ingredient also found in FDA-approved products; compounded formulations are not themselves FDA-approved.
AOD-9604
A fragment of human growth hormone studied for fat metabolism without the growth-signaling effects of full HGH.